Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
Open Access
- 1 February 2023
- journal article
- research article
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 12 (2) , e220193
Abstract
Aim:To analyze the cost–effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS).Methods:A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed.Results:CladT was the dominant treatment, with lower costs (-74,741 € [95% CI: -67,247; -85,661 €]) and greater effectiveness (0.1920 [95% CI: -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being cost-effective and a 94.1% chance of being dominant compared with DMF.Conclusion:CladT is the dominant treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain.Keywords
Funding Information
- Merck, S.L.U., Madrid, Spain, an affiliate of Merck KGaA
This publication has 50 references indexed in Scilit:
- Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitariasGaceta Sanitaria, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare PopulationValue in Health, 2009
- Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UKPharmacoEconomics, 2008
- Assessing Differences in Utility Scores: A Comparison of Four Widely Used Preference-Based InstrumentsValue in Health, 2007
- Estudio de costes de la gripeAtencion Primaria, 2006
- Natural history of multiple sclerosis: a unifying conceptBrain, 2006
- Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple SclerosisValue in Health, 2004
- A comparison of the EQ‐5D and SF‐6D across seven patient groupsHealth Economics, 2004
- Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosisBMJ, 2003